Volume 30, No 6, Jun 2020

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 30 Issue 6, June 2020: 461-462

RESEARCH HIGHLIGHTS

Enabling anti-tumor immunity by unleashing ILC2

Irene Mattiola^1,2,3 , Andreas Diefenbach^1,2,3,*

¹Laboratory of Innate Immunity, Department of Microbiology, Infectious Diseases and Immunology, Charité—Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12203 Berlin, Germany;
²Berlin Institute of Health (BIH), Anna-Louisa-Karsch Strasse 2, 10117 Berlin, Germany
³Mucosal and Developmental Immunology, Deutsches Rheuma-Forschungszentrum, Charitéplatz 1, 10117 Berlin, Germany
Correspondence: Andreas Diefenbach(andreas.diefenbach@charite.de)

Group 2 innate lymphoid cells (ILC2s) are tissue-resident lymphocytes involved in type 2 immune responses to worm infections and in the pathogenesis of allergies. Balachandran and colleagues now reveal that IL33-driven expansion of ILC2 unleashes T cell-mediated tumor immunity and that therapeutic modulation of ILC2 is a promising immunotherapeutic strategy for the treatment of pancreatic cancer, in particular when combined with PD1 checkpoint blockade.

https://doi.org/10.1038/s41422-020-0330-9

FULL TEXT | PDF

Browse 616